Unusual reactions to 5-HT3 receptor antagonists in a child with rhabdomyosarcoma.
A case of unusual reactions consisting of involuntary abnormal facial movements in a child following exposure to the 5-HT3 receptor antagonists for prophylaxis against chemotherapy-induced vomiting is presented. Potential mechanisms for these reactions are discussed.
Lee
Candace Y W
CY
Division of Clinical Pharmacology & Toxicology, Department of Paediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada.
Ratnapalan
Savithiri
S
Thompson
Margaret
M
Nathan
Paul C
PC
Closs
Jordan
J
French
Amy
A
Punnett
Angela
A
Garcia-Bournissen
Facundo
F
Ito
Shinya
S
Koren
Gideon
G
D000932:Antiemetics / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D005152:Facial Muscles / Q000187:drug effects* / Q000503:physiopathology; D006801:Humans; D008297:Male; D017294:Ondansetron / Q000009:adverse effects* / Q000627:therapeutic use; D012208:Rhabdomyosarcoma / Q000188:drug therapy; D058831:Serotonin 5-HT3 Receptor Antagonists; D012702:Serotonin Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control
D000932:Antiemetics; D000970:Antineoplastic Agents; D058831:Serotonin 5-HT3 Receptor Antagonists; D012702:Serotonin Antagonists; D017294:Ondansetron